Table 4.

Type of and reason for index therapy change within 6 months and full study period among patients who changed, N (%)

	Within 6 months		Across full study period
	Latanoprost N = 134	Travoprost-Z N = 77	Latanoprost N = 218	Travoprost-Z N = 121
Type of change
Add-on	36 (26.9)	26 (33.8)	62 (28.4)	40 (33.1)
Switch	65 (48.5)	36 (46.8)	102 (46.8)	50 (41.3)
Discontinuation	14 (10.5)	5 (6.5)	23 (10.6)	13 (10.7)
Surgery/procedure	19 (14.2)	10 (13.0)	31 (14.2)	18 (14.9)
Reason for change*
IOP not controlled	83 (61.9)	50 (64.9)	119 (54.6)	76 (62.8)
Adverse events	16 (11.9)	16 (20.8)	24 (11.0)	18 (14.9)
Physician preference	11 (8.2)	4 (5.2)	21 (9.6)	9 (7.4)
Non-compliance	8 (6.0)	2 (2.6)	11 (5.0)	6 (5.0)
Cost	9 (6.7)	3 (3.9)	19 (8.7)	4 (3.3)
Patient request	5 (3.7)	2 (2.6)	10 (4.6)	4 (3.3)
Ocular nerve head
changes	1 (0.7)	0	6 (2.8)	1 (0.8)
Other	11 (8.2)	3 (3.9)	25 (11.5)	5 (4.1)

IOP = intraocular pressure.

*Reported by ≥2% of patients in either cohort at either time point. More than one reason could be reported for each patient.